Literature DB >> 31243023

Clonidine suppression testing for pheochromocytoma in neurofibromatosis type 1.

WingYee Wan1, Bichle Nguyen1, Sky Graybill2, Jonathan Kim1.   

Abstract

Compared with the general population, rates of pheochromocytoma are higher in neurofibromatosis type 1 (NF1) patients. However, pheochromocytoma testing is often plagued by false positive results. Here we present a patient with NF1, elevated urinary metanephrine levels, and an indeterminate adrenal nodule. Clonidine suppression testing aided diagnosis and led to definitive surgical treatment that confirmed a pheochromocytoma. Pheochromocytoma screening and clonidine suppression testing can both aid in the evaluation for catecholamine-secreting tumours. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  adrenal disorders; neuro genetics

Mesh:

Substances:

Year:  2019        PMID: 31243023      PMCID: PMC6605898          DOI: 10.1136/bcr-2018-228263

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

1.  Evaluation of the clonidine suppression test in the diagnosis of phaeochromocytoma.

Authors:  C M McHenry; S J Hunter; M T McCormick; C F Russell; M G Smye; A B Atkinson
Journal:  J Hum Hypertens       Date:  2010-09-02       Impact factor: 3.012

2.  The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma.

Authors:  C G Perry; A M Sawka; R Singh; L Thabane; J Bajnarek; W F Young
Journal:  Clin Endocrinol (Oxf)       Date:  2007-03-27       Impact factor: 3.478

3.  Interest of systematic screening of pheochromocytoma in patients with neurofibromatosis type 1.

Authors:  Lori Képénékian; Thomas Mognetti; Jean-Christophe Lifante; Anne-Laure Giraudet; Claire Houzard; Stéphane Pinson; Françoise Borson-Chazot; Patrick Combemale
Journal:  Eur J Endocrinol       Date:  2016-07-22       Impact factor: 6.664

4.  Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results.

Authors:  Graeme Eisenhofer; David S Goldstein; McClellan M Walther; Peter Friberg; Jacques W M Lenders; Harry R Keiser; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

5.  The efficacy of iodine-123-MIBG as a screening test for pheochromocytoma.

Authors:  P D Mozley; C K Kim; J Mohsin; A Jatlow; E Gosfield; A Alavi
Journal:  J Nucl Med       Date:  1994-07       Impact factor: 10.057

6.  Neurofibromatosis 1 with pheochromocytoma.

Authors:  K V S Hari Kumar; Altamash Shaikh; A S Sandhu; P Prusty
Journal:  Indian J Endocrinol Metab       Date:  2011-10

7.  Type 1 neurofibromatosis and pheochromocytoma: Focus on hypertension.

Authors:  Massimiliano Rocchietti March
Journal:  J Neurosci Rural Pract       Date:  2012-01

8.  Pheochromocytoma and Neurofibromatosis Type 1 in a Patient with Hypertension.

Authors:  Julijana Petrovska; Biljana Gerasimovska Kitanovska; Stevka Bogdanovska; Svetlana Pavleska Kuzmanoska
Journal:  Open Access Maced J Med Sci       Date:  2015-12-06

9.  The importance of pheochromocytoma case detection in patients with neurofibromatosis type 1: A case report and review of literature.

Authors:  Joshua M Tate; Janelle B Gyorffy; Jeffrey A Colburn
Journal:  SAGE Open Med Case Rep       Date:  2017-11-16

10.  Pheochromocytoma and Paraganglioma in Neurofibromatosis type 1: frequent surgeries and cardiovascular crises indicate the need for screening.

Authors:  Elisabeth Joye Petr; Tobias Else
Journal:  Clin Diabetes Endocrinol       Date:  2018-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.